Antibodies News and Research

RSS

EMA issues qualification opinion for islet autoantibodies as enrichment biomarkers for T1D prevention trials

Critical Path Institute's Type 1 Diabetes Consortium (T1DC) today announced that the European Medicines Agency has issued a positive qualification opinion for pancreatic islet autoantibodies as enrichment biomarkers for type 1 diabetes (T1D) prevention trials.

5 Apr 2022

SARS-CoV-2 Omicron breakthrough infections induce antibodies with cross-variant neutralization potential and recall memory B cells

Researchers reported breakthrough infections by SARS-CoV-2’s new variant of concern, Omicron, that elicited broadly cross-reactive neutralizing antibodies in the BNT162b2-vaccinated individuals.

5 Apr 2022

Pre-existing memory B cell dynamics during SARS-CoV-2 Omicron breakthrough infection

A new study analyzed the recall of pre-existent cross-reactive memory B cells upon the SARS-CoV-2 Omicron breakthrough infections.

5 Apr 2022

Investigating extensive SARS-CoV-2 neutralizing immunoglobulins from COVID-19 recovered subjects

A new study discovered immunoglobulins with powerful broad-acting neutralizing capacity against SARS-CoV-2 from SARS-CoV-2 convalescents.

5 Apr 2022

“MixOmicron” SARS-CoV-2 recombinant evades variant screening

A new study describes a new variant that resembles the SARS-CoV-2 Omicron BA.21 for the most part but has a small segment at the 3’ tip that belongs to the BA.1 variant.

5 Apr 2022

Study generates a picture of the myocardial transcriptional landscape of COVID-19

Researchers profiled cardiac tissue transcriptomes of COVID-19 patients.

5 Apr 2022

Prior COVID vaccination induces a more robust antibody response to Omicron

A recent study posted to the medRxiv* preprint server assessed the impact of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination on the human immune response against SARS-CoV-2 Omicron infection.

5 Apr 2022

Study on the efficacy of a BNT162b2 booster dose in the elderly

In a recent study posted to the medRxiv* preprint server, researchers characterized the immune responses against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant after receiving a booster dose of BNT162b2 vaccine in older people.

5 Apr 2022

The SAVE initiative to monitor the impact of SARS-CoV-2 variants

The SAVE initiative assesses the impact of SARS-CoV-2 variants on diagnostics, vaccines, and therapies, as well as communicating public health dangers.

4 Apr 2022

BNT162b2 booster vaccine provides equal protection against BA.1 and BA.2

Researchers compare the neutralization of BA.1 and BA.2 strains in immunized people who had received two doses and a booster BNT162b2 mRNA vaccine.

4 Apr 2022

Key protein could be a novel target for treatment of patients with B cell signaling deficiencies

The rules to the kids' game "red light, green light" are easy to follow: red always means stop, and green always means go. But now, researchers from Japan have found that a key protein involved in B cell signaling acts as both a red light to signaling in healthy cells and a green light to signaling in immune-deficient cells.

4 Apr 2022

Magnitude and durability of SARS-CoV-2 S-binding antibody titers in the pre-variant era among healthcare workers in NYC

Researchers analyzed sera samples of 400 participants of the PARIS study to evaluate the risk of SARS-CoV-2 infection and seroreversion for an average of 84 days.

4 Apr 2022

Study investigates targeted phenotyping of host proteins aiding drug repurposing in COVID-19

Researchers conducted selective phenotyping of coronavirus disease 2019 -relevant host proteins to facilitate target identification for drug repurposing.

4 Apr 2022

SARS-CoV-2 prevalence during the initial period of SARS-CoV-2 Omicron variant emergence in Finland

A recent study presented the rapid spike in COVID-19 seroprevalence during the emergence of the Omicron variant in Finland.

4 Apr 2022

Study shows SARS-CoV-2 antibodies persist for one-year post-infection with protection from other variants

Researchers discussed the stability of spike antibody titers mounted against SARS-CoV-2 infection, and their ability to protect from infection with antigenically similar variants.

4 Apr 2022

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

In a recent study published in the journal Science, researchers observed differential effector functions of antibodies elicited by Pfizer’s BNT162b2 and Moderna’s messenger ribonucleic acid (mRNA)-1273 coronavirus disease 2019 (COVID-19) vaccines.

4 Apr 2022

The effect of COVID-19 on the lung function of young adults

Researchers evaluate whether SARS-CoV-2 infection has a negative impact on lung function in young adults who experienced mild to moderate COVID-19.

3 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Groundbreaking collaborative work defines the risk of SARS-CoV-2 variants on immune protection

In a paper in the journal Nature, Los Alamos National Laboratory scientists Bette Korber, Hyejin Yoon, Will Fischer and James Theiler, among nearly 130 authors from institutions around the world, describe their groundbreaking collaborative work, "Defining the risk of SARS-CoV-2 variants on immune protection."

1 Apr 2022

Research illuminates why immune disorders affect only one of two identical twins

Scientists have long queried the causes of immune disorders in only one of two identical twins with identical genes. New research from the Wellcome Sanger Institute, the Josep Carreras Leukaemia Research Institute in Spain and their collaborators, has found the answer lies in both alterations in immune cell-cell communication and the epigenome, the host of biological processes that regulate how our genes function.

1 Apr 2022

Antibodies News and Research

EMA issues qualification opinion for islet autoantibodies as enrichment biomarkers for T1D prevention trials

SARS-CoV-2 Omicron breakthrough infections induce antibodies with cross-variant neutralization potential and recall memory B cells

Pre-existing memory B cell dynamics during SARS-CoV-2 Omicron breakthrough infection

Investigating extensive SARS-CoV-2 neutralizing immunoglobulins from COVID-19 recovered subjects

“MixOmicron” SARS-CoV-2 recombinant evades variant screening

Study generates a picture of the myocardial transcriptional landscape of COVID-19

Prior COVID vaccination induces a more robust antibody response to Omicron

Study on the efficacy of a BNT162b2 booster dose in the elderly

The SAVE initiative to monitor the impact of SARS-CoV-2 variants

BNT162b2 booster vaccine provides equal protection against BA.1 and BA.2

Key protein could be a novel target for treatment of patients with B cell signaling deficiencies

Magnitude and durability of SARS-CoV-2 S-binding antibody titers in the pre-variant era among healthcare workers in NYC

Study investigates targeted phenotyping of host proteins aiding drug repurposing in COVID-19

SARS-CoV-2 prevalence during the initial period of SARS-CoV-2 Omicron variant emergence in Finland

Study shows SARS-CoV-2 antibodies persist for one-year post-infection with protection from other variants

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

The effect of COVID-19 on the lung function of young adults

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Groundbreaking collaborative work defines the risk of SARS-CoV-2 variants on immune protection

Research illuminates why immune disorders affect only one of two identical twins

A new way of characterising biomolecules eBook

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices

Latest Life Science News